
- /
- Supported exchanges
- / US
- / MTSR.NASDAQ
Metsera, Inc. Common Stock (MTSR NASDAQ) stock market data APIs
Metsera, Inc. Common Stock Financial Data Overview
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Metsera, Inc. Common Stock data using free add-ons & libraries
Get Metsera, Inc. Common Stock Fundamental Data
Metsera, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Metsera, Inc. Common Stock News

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?
Metsera Inc. (MTSR) closed the last trading session at $29.00, gaining 6.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Stre...


Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event
[GLP-1 related drugs newspaper headlines with hand and magnifying glass] Leading weight loss drug developers Eli Lilly (NYSE:LLY [https://seekingalpha.com/symbol/LLY]), Novo Nordisk (NVO [https://see...

Metsera stock initiated at overweight by Wells Fargo on obesity drug
Investing.com - Wells Fargo initiated coverage on Metsera Inc (NASDAQ:MTSR), a $2.91 billion biotech company trading at $27.71, with an overweight rating and a $65.00 price target on Friday. The pri...

Eli Lilly’s early-stage obesity drug causes up to 11% of weight loss in three months
[Indianapolis - April 2016: Eli Lilly and Company VII] jetcityimage/iStock Editorial via Getty Images Eli Lilly’s (NYSE:LLY [https://seekingalpha.com/symbol/LLY]) experimental obesity therapy elora...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.